Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562 chronic myleoid leukemia cells to imatinib

Journals Menu

Follow SCIRP

ISSN Print: 1949-4998
ISSN Online: 1949-5005
www.scirp.org/journal/health
E-mail: health@scirp.org

"Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562 chronic myleoid leukemia cells to imatinib"
written by Baran Yusuf, Coskun Oztekin, Bassoy Esen Yonca,
published by Health, Vol.1 No.4, 2009

has been cited by the following article(s):

[1]	The Effects of Commonly Used Antibiotic Medications on the Efficacy of Tyrosine Kinase Inhibitors in Philadelphia Chromosome Positive Leukemia
	2017

[2]	c-Abl Regulates Proteasome Abundance by Controlling the Ubiquitin-Proteasomal Degradation of PSMA7 Subunit
	Cell Reports, 2015

[1]	Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells Biomolecular Concepts, 2021 DOI:10.1515/bmc-2021-0016

[2]	Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells Biomolecular Concepts, 2021 DOI:10.1515/bmc-2021-0016

[3]	c-Abl Regulates Proteasome Abundance by Controlling the Ubiquitin-Proteasomal Degradation of PSMA7 Subunit Cell Reports, 2015 DOI:10.1016/j.celrep.2014.12.044

Follow SCIRP

Free SCIRP Newsletters

Add your e-mail address to receive free newsletters from SCIRP.

Top